Elekta and IBA strengthen partnership to help cancer centers integrate proton therapy

Over 160 California Auctions End Today - Bid Now
Over 300 Total Lots Up For Auction at One Location - NJ 05/24

Elekta and IBA strengthen partnership to help cancer centers integrate proton therapy

Press releases may be edited for formatting or style | March 08, 2021 Rad Oncology Proton Therapy

Elekta and IBA have been collaborating for the last 20 years to help oncology centers integrate the cancer treatment modality into their patient care environment.


About Elekta

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.


For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.


SOURCE Elekta

Back to HCB News

You Must Be Logged In To Post A Comment